BCLI Quote, Financials, Valuation and Earnings

NanoViricides, Inc. has a net margin of -- compared to Brainstorm Cell Therapeutics, Inc.'s net margin of --. Brainstorm Cell Therapeutics, Inc.'s return on equity of -- beat NanoViricides, Inc.'s return on equity of -92.29%.

Brainstorm Cell Therapeutics, Inc. has a consensus price target of $20.68, signalling upside risk potential of 3345.83%. On the other hand NanoViricides, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 469.11%. Given that Brainstorm Cell Therapeutics, Inc. has higher upside potential than NanoViricides, Inc., analysts believe Brainstorm Cell Therapeutics, Inc. is more attractive than NanoViricides, Inc..

Brainstorm Cell Therapeutics, Inc. has a beta of -0.928, which suggesting that the stock is 192.842% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.

Brainstorm Cell Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Brainstorm Cell Therapeutics, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.

Brainstorm Cell Therapeutics, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. Brainstorm Cell Therapeutics, Inc.'s net income of -$2.1M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, Brainstorm Cell Therapeutics, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Brainstorm Cell Therapeutics, Inc. is -- versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics, Inc. has a net margin of -- compared to Brainstorm Cell Therapeutics, Inc.'s net margin of --. Brainstorm Cell Therapeutics, Inc.'s return on equity of -- beat Oragenics, Inc.'s return on equity of -509.23%.

Brainstorm Cell Therapeutics, Inc. has a consensus price target of $20.68, signalling upside risk potential of 3345.83%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 126.37%. Given that Brainstorm Cell Therapeutics, Inc. has higher upside potential than Oragenics, Inc., analysts believe Brainstorm Cell Therapeutics, Inc. is more attractive than Oragenics, Inc..

Brainstorm Cell Therapeutics, Inc. has a beta of -0.928, which suggesting that the stock is 192.842% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.

Brainstorm Cell Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Brainstorm Cell Therapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.

Brainstorm Cell Therapeutics, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Brainstorm Cell Therapeutics, Inc.'s net income of -$2.1M is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, Brainstorm Cell Therapeutics, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Brainstorm Cell Therapeutics, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Brainstorm Cell Therapeutics, Inc.'s net margin of --. Brainstorm Cell Therapeutics, Inc.'s return on equity of -- beat Palatin Technologies's return on equity of --.

Brainstorm Cell Therapeutics, Inc. has a consensus price target of $20.68, signalling upside risk potential of 3345.83%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Brainstorm Cell Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Brainstorm Cell Therapeutics, Inc..

Brainstorm Cell Therapeutics, Inc. has a beta of -0.928, which suggesting that the stock is 192.842% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Brainstorm Cell Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Brainstorm Cell Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Brainstorm Cell Therapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Brainstorm Cell Therapeutics, Inc.'s net income of -$2.1M is higher than Palatin Technologies's net income of --. Notably, Brainstorm Cell Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Brainstorm Cell Therapeutics, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -- compared to Brainstorm Cell Therapeutics, Inc.'s net margin of --. Brainstorm Cell Therapeutics, Inc.'s return on equity of -- beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Brainstorm Cell Therapeutics, Inc. has a consensus price target of $20.68, signalling upside risk potential of 3345.83%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3004.21%. Given that Brainstorm Cell Therapeutics, Inc. has higher upside potential than Theriva Biologics, Inc., analysts believe Brainstorm Cell Therapeutics, Inc. is more attractive than Theriva Biologics, Inc..

Brainstorm Cell Therapeutics, Inc. has a beta of -0.928, which suggesting that the stock is 192.842% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Brainstorm Cell Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Brainstorm Cell Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Brainstorm Cell Therapeutics, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Brainstorm Cell Therapeutics, Inc.'s net income of -$2.1M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Brainstorm Cell Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Brainstorm Cell Therapeutics, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.